228 related articles for article (PubMed ID: 26428606)
1. SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES.
Brown MM; Brown GC; Lieske HB; Tran I; Turpcu A; Colman S
Retina; 2016 Feb; 36(2):285-98. PubMed ID: 26428606
[TBL] [Abstract][Full Text] [Related]
2. Burden of illness of neovascular age-related macular degeneration in Canada.
Cruess A; Zlateva G; Xu X; Rochon S
Can J Ophthalmol; 2007 Dec; 42(6):836-43. PubMed ID: 18026200
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
[TBL] [Abstract][Full Text] [Related]
5. Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008.
Qualls LG; Hammill BG; Wang F; Lad EM; Schulman KA; Cousins SW; Curtis LH
Retina; 2013 Apr; 33(4):854-61. PubMed ID: 23296047
[TBL] [Abstract][Full Text] [Related]
6. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
Brown GC; Brown MM; Turpcu A; Rajput Y
Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
[TBL] [Abstract][Full Text] [Related]
7. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
Coleman AL; Yu F
Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of multimorbidity among older adults: impact on healthcare and societal costs.
Picco L; Achilla E; Abdin E; Chong SA; Vaingankar JA; McCrone P; Chua HC; Heng D; Magadi H; Ng LL; Prince M; Subramaniam M
BMC Health Serv Res; 2016 May; 16():173. PubMed ID: 27160080
[TBL] [Abstract][Full Text] [Related]
9. Medicare costs for neovascular age-related macular degeneration, 1994-2007.
Day S; Acquah K; Lee PP; Mruthyunjaya P; Sloan FA
Am J Ophthalmol; 2011 Dec; 152(6):1014-20. PubMed ID: 21843875
[TBL] [Abstract][Full Text] [Related]
10. Financial return-on-investment of ophthalmic interventions: a new paradigm.
Brown MM; Brown GC; Lieske HB; Lieske PA
Curr Opin Ophthalmol; 2014 May; 25(3):171-6. PubMed ID: 24638114
[TBL] [Abstract][Full Text] [Related]
11. Neovascular age-related macular degeneration associated with no light perception.
Brown GC; Basha MM; Brown MM
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):229-34. PubMed ID: 25707049
[TBL] [Abstract][Full Text] [Related]
12. Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study.
Prenner JL; Halperin LS; Rycroft C; Hogue S; Williams Liu Z; Seibert R
Am J Ophthalmol; 2015 Oct; 160(4):725-31.e1. PubMed ID: 26142721
[TBL] [Abstract][Full Text] [Related]
13. The burden of age-related macular degeneration: a value-based medicine analysis.
Brown GC; Brown MM; Sharma S; Stein JD; Roth Z; Campanella J; Beauchamp GR
Trans Am Ophthalmol Soc; 2005; 103():173-84; discussion 184-6. PubMed ID: 17057801
[TBL] [Abstract][Full Text] [Related]
14. Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration.
Gohil R; Crosby-Nwaobi R; Forbes A; Burton B; Hykin P; Sivaprasad S
PLoS One; 2015; 10(6):e0129361. PubMed ID: 26056840
[TBL] [Abstract][Full Text] [Related]
15. Patterns and costs associated with progression of age-related macular degeneration.
Schmier JK; Covert DW; Lau EC
Am J Ophthalmol; 2012 Oct; 154(4):675-681.e1. PubMed ID: 22835513
[TBL] [Abstract][Full Text] [Related]
16. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom.
Angelis A; Kanavos P; López-Bastida J; Linertová R; Serrano-Aguilar P;
BMC Musculoskelet Disord; 2016 Aug; 17():321. PubMed ID: 27484740
[TBL] [Abstract][Full Text] [Related]
17. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT).
Maguire M;
Ophthalmology; 2004 Jul; 111(7):1307-16. PubMed ID: 15234130
[TBL] [Abstract][Full Text] [Related]
18. The burden of age-related macular degeneration.
Schmier JK; Jones ML; Halpern MT
Pharmacoeconomics; 2006; 24(4):319-34. PubMed ID: 16605279
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of teleophthalmology in screening and recurrence monitoring of neovascular age-related macular degeneration: a randomized clinical trial.
Li B; Powell AM; Hooper PL; Sheidow TG
JAMA Ophthalmol; 2015 Mar; 133(3):276-82. PubMed ID: 25473945
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
